W. Jonat

16.4k total citations · 3 hit papers
298 papers, 9.8k citations indexed

About

W. Jonat is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, W. Jonat has authored 298 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 101 papers in Cancer Research and 93 papers in Genetics. Recurrent topics in W. Jonat's work include Estrogen and related hormone effects (73 papers), Breast Cancer Treatment Studies (72 papers) and Cancer Treatment and Pharmacology (38 papers). W. Jonat is often cited by papers focused on Estrogen and related hormone effects (73 papers), Breast Cancer Treatment Studies (72 papers) and Cancer Treatment and Pharmacology (38 papers). W. Jonat collaborates with scholars based in Germany, United States and United Kingdom. W. Jonat's co-authors include W. Eiermann, Manfred Kaufmann, Christoph Mundhenke, Anthony Howell, Nicolaì Maass, Carl Blomqvist, Michael Gnant, Gϋnter von Minckwitz, Liselotte Mettler and İbrahim Alkatout and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

W. Jonat

283 papers receiving 9.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

2005 642 citations W. Jonat, Michael Gnant et al. profile →
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

2006 548 citations W. Eiermann, W. Jonat et al. Journal of Clinical Oncology profile →
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer

2009 504 citations José Baselga, Alexey Manikhas et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
W. Jonat Germany	48	4.7k	3.7k	3.3k	2.0k	1.7k	298	9.8k
Lynn C. Hartmann United States	59	4.9k 1.0×	4.4k 1.2×	3.9k 1.2×	3.2k 1.6×	1.2k 0.7×	203	13.0k
R. Kreienberg Germany	54	4.3k 0.9×	3.4k 0.9×	934 0.3×	2.1k 1.1×	1.3k 0.8×	434	10.6k
Peggy L. Porter United States	60	7.5k 1.6×	3.9k 1.1×	2.0k 0.6×	4.1k 2.1×	1.7k 1.0×	140	13.3k
Kunle Odunsi United States	60	7.2k 1.5×	2.1k 0.6×	978 0.3×	5.0k 2.5×	1.5k 0.8×	370	15.5k
Helena Earl United Kingdom	40	3.5k 0.7×	2.0k 0.6×	1.1k 0.3×	1.9k 1.0×	1.3k 0.7×	194	6.5k
Henrik Grönberg Sweden	57	2.6k 0.5×	2.5k 0.7×	2.0k 0.6×	3.2k 1.6×	5.2k 3.0×	263	11.6k
Christian Marth Austria	61	5.3k 1.1×	2.8k 0.8×	1.6k 0.5×	5.8k 2.9×	1.3k 0.8×	411	14.0k
Patrice Viens France	61	10.5k 2.2×	5.6k 1.5×	1.1k 0.3×	6.0k 3.0×	2.8k 1.6×	353	17.5k
J. Michael Dixon United Kingdom	54	4.1k 0.9×	5.3k 1.4×	2.6k 0.8×	2.5k 1.3×	1.4k 0.8×	270	10.8k
William T. Barry United States	47	4.3k 0.9×	2.4k 0.7×	967 0.3×	2.1k 1.1×	1.6k 0.9×	191	8.4k

Countries citing papers authored by W. Jonat

Since Specialization

Citations

This map shows the geographic impact of W. Jonat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Jonat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Jonat more than expected).

Fields of papers citing papers by W. Jonat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Jonat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Jonat. The network helps show where W. Jonat may publish in the future.

Co-authorship network of co-authors of W. Jonat

This figure shows the co-authorship network connecting the top 25 collaborators of W. Jonat. A scholar is included among the top collaborators of W. Jonat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W. Jonat. W. Jonat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Smith, Ian, Denise A. Yardley, Howard A. Burris, et al.. (2017). Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. Journal of Clinical Oncology. 35(10). 1041–1048. 68 indexed citations

Schem, Christian, Dirk Bauerschlag, Frank Rösel, et al.. (2013). Preclinical evaluation of Sunitinib as a single agent in the prophylactic setting in a mouse model of bone metastases. BMC Cancer. 13(1). 32–32. 6 indexed citations

Alkatout, İbrahim, Liselotte Mettler, Jürgen Hedderich, et al.. (2013). Combined Surgical and Hormone Therapy for Endometriosis is the Most Effective Treatment: Prospective, Randomized, Controlled Trial. Journal of Minimally Invasive Gynecology. 20(4). 473–481. 69 indexed citations

Iwata, Hiroji, José Baselga, Mario Campone, et al.. (2013). Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.. Journal of Clinical Oncology. 31(15_suppl). TPS650–TPS650. 8 indexed citations

Schüler, Martin, Ahmad Awada, Philipp Harter, et al.. (2012). A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 134(3). 1149–1159. 71 indexed citations

Wenners, Antonia, Keyur Mehta, Sibylle Loibl, et al.. (2012). Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer. PLoS ONE. 7(10). e45826–e45826. 44 indexed citations

Stemmler, Hans‐Joachim, Werner Freier, G. Gitsch, et al.. (2011). Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. British Journal of Cancer. 104(7). 1071–1078. 29 indexed citations

Untch, Michael, M Muscholl, Sergei Tjulandin, et al.. (2010). First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial. Journal of Clinical Oncology. 28(9). 1473–1480. 55 indexed citations

Stark, Andreas M., Christian Schem, Nicolaì Maass, et al.. (2009). Expression of metastasis suppressor gene maspin is reduced in breast cancer brain metastases and correlates with the estrogen receptor status. Neurological Research. 32(3). 303–308. 20 indexed citations

10.

Mundhenke, Christoph, Christian Schem, & W. Jonat. (2008). Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer. Breast Care. 3(5). 317–324. 1 indexed citations

11.

Meinhold‐Heerlein, Ivo, Dirk Bauerschlag, Yingyao Zhou, et al.. (2007). An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma. Clinical Cancer Research. 13(2). 458–466. 41 indexed citations

12.

Nagasaki, Koichi, Christian Schem, Constantin von Kaisenberg, et al.. (2003). Leucine‐zipper protein, LDOC1, inhibits NF‐κB activation and sensitizes pancreatic cancer cells to apoptosis. International Journal of Cancer. 105(4). 454–458. 67 indexed citations

13.

Jonat, W., et al.. (2003). Phase Ii study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer -final results of the German Neoadjuvant Aromasin Initiative (genari). Breast Cancer Research and Treatment. 82. 17 indexed citations

14.

Ohike, Nobuyuki, Nicolaì Maass, Christoph Mundhenke, et al.. (2003). Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Letters. 199(2). 193–200. 46 indexed citations

15.

Kaufmann, M., W. Jonat, R.W. Blarney, et al.. (2002). Updated survival results from the Zebra trial.. Breast Cancer Research and Treatment. 76. 2 indexed citations

16.

Jonat, W.. (1998). Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer. British Journal of Cancer. 78(S4). 5–8. 21 indexed citations

17.

Jonat, W., Anthony Howell, Carl Blomqvist, et al.. (1996). A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *. European Journal of Cancer. 32(3). 404–412. 207 indexed citations

18.

Jonat, W., M. Kaufmann, & Klaus Munk. (1995). Hormone-dependent tumors ; basic research and clinical studies. KARGER eBooks. 1 indexed citations

19.

Mertens, H. G. & W. Jonat. (1978). [Bilateral carcinoma of the breast after radiotherapy and chemotherapy for Hodgkin's disease (author's transl)].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(11). 968–70. 1 indexed citations

20.

Jonat, W. & Heinrich Maass. (1978). Some comments on the necessity of receptor determination in human breast cancer.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(11 Pt 2). 4305–6. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact